Table 1 Baseline characteristics of treatment groups
Characteristic | PMX-HP group (n = 29) | Non-PMX-HP group (n = 30) | P valuea |
|---|---|---|---|
Age (years), mean (SD) | 70.2 (13.0) | 67.4 (14.6) | 0.43 |
Male, n (%) | 23 (79) | 17 (57) | 0.06 |
BMI (kg/m2), mean (SD) | 24.2 (4.3) | 23.5 (4.7) | 0.62 |
Baseline serum creatinine (mg/dl), median (Q1, Q3) | 1.0 (1.0, 1.1) | 1.0 (0.8, 1.1) | 0.48 |
BUN at enrollment (mg/dl), median (Q1, Q3) | 41 (26, 63) | 41 (22, 62) | 0.65 |
Serum creatinine at enrollment (mg/dl), median (Q1, Q3) | 2.2 (1.6, 3.1) | 2.6 (1.8, 4.0) | 0.34 |
AKI, n (%) | Â | Â | 0.16 |
 Non-AKI | 4 (14) | 5 (17) |  |
 Stage 1 | 8 (28) | 4 (13) |  |
 Stage 2 | 9 (31) | 5 (17) |  |
 Stage 3 | 8 (28) | 16 (53) |  |
RRT, n (%) | 27 (93) | 20 (69) | 0.02 |
  CRRT | 21 (72%) | 14 (48%) |  |
  SLED | 6 (21%) | 4 (14%) |  |
  Peritoneal dialysis | 0 (0%) | 2 (7%) |  |
SOFA score, mean (SD) | 13.8 (4.4) | 13.3 (5.0) | 0.71 |
Type of fluid, n (%) | |||
 Crystalloid | 23 (79) | 23 (77) | 0.81 |
 Colloid | 15 (52) | 13 (43) | 0.52 |
Inotrope/vasopressor use, n (%) | 25 (86) | 25 (83) | > 0.99 |
 Adrenaline | 8 (28) | 6 (20) | 0.49 |
 Noreadrenaline | 20 (69) | 22 (73) | 0.71 |
 Dopamine | 8 (28) | 4 (13) | 0.17 |
 Dobutamine | 4 (14) | 3 (10) | 0.71 |
 Vasopressin | 0 (0) | 0 (0) | > 0.99 |
 Terlipressin | 1 (3) | 0 (0) | 0.49 |
Inotropic score (μg/kg/min), median (Q1, Q3) | 36 (7, 70) | 30 (2, 83) | 0.96 |
Vasopressor index (μg/kg/min/mmHg), median (Q1, Q3) | 0.4 (0.1, 1.1) | 0.4 (0.1, 1.1) | 0.93 |
EAA at enrollment, median (Q1, Q3) | 0.8 (0.7, 1.0) | 0.7 (0.7, 0.9) | 0.24 |
Presepsin (pg/ml), median (Q1, Q3) | 5514 (4088, 10,513) | 5030 (2459, 10,734) | 0.47 |